Skip to content
DataLookout
Menu

NCT07850050

SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below.

  1. Notable Recruitment opened
    • Trial sites expanded: 16 → 46 locations
    • Start date pushed from Oct 31, 2026 to Nov 25, 2026
  2. Minor Trial sites expanded: 13 → 16 locations
  3. Minor Trial sites expanded: 1 → 13 locations
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage change in body weight from baseline to Week 52
Timeframe: At baseline and Week 52

Secondary (20)

Key secondary endpoint: Absolute change in IWQOL-Lite CT total scale score (units on a scale) from baseline to Week 52
Absolute change in IWQOL-Lite CT physical scale score (units on a scale) from baseline to Week 52
Absolute change in IWQOL-Lite CT physical function scale score (units on a scale) from baseline to Week 52
Absolute change in IWQOL-Lite CT psychosocial scale score (units on a scale) from baseline to Week 52
Absolute change in patient-reported outcome 1 from baseline to Week 52
Show 15 moreShow less
Absolute change in patient-reported outcome 2 frequency from baseline to Week 52
Absolute change in patient-reported outcome 2 severity from baseline to Week 52
Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 52
Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 52
Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 52
Absolute change in PROMIS Physical Function score (PF-SF10a) (units on a scale) from baseline to Week 52
Absolute change in Body Mass Index (BMI) (kg/m2) from baseline to Week 52
Absolute in waist circumference (cm) from baseline to Week 52
Absolute change in systolic blood pressure (mmHg) from baseline to Week 52
Absolute change in Glycosylated Haemoglobin A1c (HbA1c) (%) from baseline to Week 52
Relative change in Low-Density Lipoprotein (LDL) cholesterol (%) from baseline to Week 52
Relative change in triglycerides (%) from baseline to Week 52
Relative change in High-Density Lipoprotein (HDL) (%) from baseline to Week 52
Relative change in non-HDL (%) from baseline to Week 52
Relative change in high sensitivity C-reactive protein (hsCRP) (%) from baseline to Week 52

Arms and interventions

Survodutide armExperimental
Placebo armPlacebo comparator

Combination products: Survodutide, Placebo

Sites

46 sites in 4 countries

United States 16, Germany 11, United Kingdom 11, Spain 8